Immunotherapy plus radiotherapy for stomach/esophagus cancer
Part of Ear, nose & throat clinical trials.
This trial tests combining immunotherapy with radiation for a specific type of stomach or esophagus cancer that has a genetic marker called dMMR/MSI-H. It aims to see if this combination can help people who haven't had any prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer of the stomach or where the stomach meets the esophagus, and it has spread to nearby lymph nodes but not to distant organs.
- Your cancer has a specific genetic feature called dMMR or MSI-H, which is found by testing a biopsy sample.
- You haven't had any chemotherapy, radiation, immunotherapy, or other cancer treatment before.
- You are between 18 and 80 years old and are in good enough health to be up and about (ECOG score 0-1).
- Your blood counts and organ function (kidney, liver) are within certain safe ranges.
- You are willing to use effective birth control during the study and for several months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining an immunotherapy drug (sintilimab) with low-dose radiation before surgery for stomach cancer that has a specific genetic marker (dMMR/MSI-H). The goal is to see if this combination can shrink the tumor and improve outcomes without needing strong chemo.
This trial tests whether combining immunotherapy with chemotherapy before surgery can help treat adenocarcinoma of the esophagus and stomach junction. It aims to improve outcomes for patients whose cancer can be surgically removed.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of low-dose radiotherapy, chemotherapy, and an immunotherapy drug (tislelizumab) before and after surgery for locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This trial studies giving immunotherapy together with chemotherapy and radiation before surgery for esophagogastric junction cancer. It aims to shrink the tumor and improve outcomes for people with early locally advanced, HER2-negative disease.
Hear when a new Esophagogastric Junction/Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.